EU/3/10/762

About

On 4 August 2010, orphan designation (EU/3/10/762) was granted by the European Commission to Wyeth Europa Limited, United Kingdom, for bosutinib for the treatment of chronic myeloid leukaemia.

The sponsorship was transferred to Pfizer Limited, United Kingdom, in May 2011.

Bosutinib has been authorised in the EU as Bosulif since 27 March 2013.

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2018 upon request of the marketing authorisation holder at the time of the granting of a change to the terms of the marketing authorisation.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Bosutinib
Medicine name
Bosulif
Disease / condition
Treatment of chronic myeloid leukaemia
Date of decision
04/08/2010
Outcome
Withdrawn
Orphan decision number
EU/3/10/762

Review of designation

In March 2018 the Committee for Orphan Medicinal Products reviewed the orphan designation of Bosulif at the time of the granting of a change to the terms of the marketing authorisation.

The sponsor formally requested the withdrawal of the orphan designation prior to the Committee's final opinion. More information is available in the PDF iconwithdrawal assessment report - orphan maintenance .

On 12 February 2013, the Committee for Orphan Medicinal Products (COMP) finalised the review of the designation EU/3/10/762 for Bosulif (bosutinib) as an orphan medicinal product for the treatment chronic myeloid leukaemia (CML). The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other satisfactory methods of treatment. As other satisfactory methods of treatment for patients with this condition are authorised in the European Union (EU), the COMP also looked at the significant benefit of the product over existing treatments. The COMP recommended that the orphan designation of the medicine be maintained1.


1The maintenance of the orphan designation at time of marketing authorisation would, except in specific situations, give an orphan medicinal product 10 years of market exclusivity in the EU. This means that in the 10 years after its authorisation similar products with a comparable therapeutic indication cannot be placed on the market.

Sponsor's contact details

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom
Tel. +44 (0)1304 616 161
Fax +44 (0)1304 652 144
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating